The NKC Huygens Catheter™ (pictured on the left) and the Proteus™ Robotic Arm (pictured on the right) represent a visionary step forward in advasncing the ability of the EP Physician to diagnose and treat patients with arrythmia-based casrdia disease. 

BioSig PURE™EP

Both NKC and BioSig have signed a non-binding Letter of Intent (LOI) to outline the parameters of the transaction being discussed. The LOI confirms BioSig’s interest in the acquisition of NKC’s assets. The purchase price will be paid through the issuance of shares of BioSig’s common stock to the shareholders of NKC. In addition, NKC will provide a minimum of $2.5 million at closing but could provide up to $6 million, of unrestricted cash to BioSig. The proposed acquisition will require extensive due diligence, potentially through year-end, with full disclosures in the Company’s next proxy statement for shareholder vote.

BioSig was a publiclly traded company on the NASDAQ but is currently listed on the OTC market. It is hoped with the acguisition of the NKC IP, BioSig’s equity position and market positioning for advsncing the combined technology will prove to be a viable opportunity for the established and broader investment base. The generation interest and investment shoul result in a significant stock value increase and a quick return to the NASDAQ stock exchange.

BioSig CEO Anthony Amato

BioSig’s CEO, Anthony Amato stated, “The Company’s management team and board of directors are strategically aligned to continue to execute attainable goals for 2024. We feel we have the ability to leverage our improving balance sheet, along with our expertise, to expand our product portfolio beyond PURE EP™.  With this in mind, we will continue to evaluate opportunities with a focus on new and exciting innovative technological platforms. I want to thank the NKC team for recognizing our complimentary core technologies and providing the initial due diligence. I look forward to the progression of this process.”

NKC CEO Josh Shachar

Neuro-Kinesis’ CEO, Josh Shachar stated, “I’m very excited about the potential collaboration with BioSig. Joining forces will enable us to accelerate the market entry of our breakthrough technology for the diagnostic and therapeutic treatment of complex cardiac arrhythmias. For the last couple of decades, EP physicians have relied on an equal amount of historical results: the bioelectric voltage realms they can measure, and intuitive instincts they have learned to guide their healing art. The Huygens™ Catheter should allow them to finally be able to visualize the low-voltage landscape of the heart, where many believe the important information related to complex arrythmias lie.”

Both parties are diligently pursuing the proposed deal and hope to make a progress announcement on the negotiastions shrotly.

About NKC

NKC is an advanced medical technology company based in Los Angeles that focuses on the development of its patented catheter-based diagnostic system that is aimed at addressing the limitations of the existing art of EP mapping. The centerpieces of this technology are the Huygens™ Catheter, which aims to improve the resolution of signal detection by a significant order of magnitude, and the Proteus™ Robotic Arm, which delivers to the physician a computer-assisted robotic guidance system for EP catheters that significantly improves the accuracy and repeatability of anatomical target acquisition during mapping, ablation, and other EP-related procedures. NKC brings new opportunities to the EP market, as the Huygens™ Catheter allows for improved signal processing, which is crucial for better treatment of arrhythmia. Following regulatory approval, NKC will be able to sell its consumables technology in a variety of lucrative markets.

About BioSig

BioSig Technologies is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. Their PURE EP™ Platform, delivers new levels of clarity in arrhythmia identification and visualization, empowering physicians with actionable insights. The PURE EP™ tech nology provides configurable features, unique algorithms and signal hygiene applications, resulting in freedom for the EP physician  to explore relevant signal data for highly tailored, efficient procedures.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) BioSig’s ability to acquire NKC, conduct its business and obtain financing on commercially reasonable terms if and when needed; (ii) BioSig’s ability to manufacture its products and product candidates on a commercial scale on its own, or in collaboration with third parties; (iii) BioSig’s current or future competitors expanding the size and nature of their respective commercial activities; (iv) BioSig’s loss of one or more of its key executives or scientists; and (v) BioSig’s difficulties in securing regulatory approval to market its products and product candidates. For a discussion of other risks and uncertainties, and other important factors, any of which could cause BioSig’s actual results to differ from those contained in forward-looking statements, see BioSig’s filings with the Securities and Exchange Commission (“SEC”), including the section titled “Risk Factors” in BioSig’s Annual Report on Form 10‑K, filed with the SEC on April 16, 2024 and subsequent filings. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation publicly to update or revise its forward-looking statements as a result of new information, future events or otherwise, except as required by law.